RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000068.xml
PDF herunterladen
Semin intervent Radiol 2020; 37(05): 518-526
DOI: 10.1055/s-0040-1720949
DOI: 10.1055/s-0040-1720949
Review Article
Hepatic Metastasis from Breast Cancer
Funding This research was funded through the NIH/NCI Cancer Center Support Grant P30 CA008748. A.R.D. reports personal fees from BTG, Inc. and from Dova Pharmaceuticals, outside the submitted work.
Abstract
Breast cancer is the most common cancer in women and breast cancer liver metastasis may be associated with poor outcomes. Emerging locoregional therapies can be given in outpatient settings or with short hospital stays, to provide local control, support quality of life, preserve liver function, and potentially prolong survival. This review discusses retrospective studies suggesting potential benefits of locoregional treatment of breast cancer liver metastasis. Future prospective studies are needed to demonstrate efficacy and optimize patient selection.
Keywords
breast cancer - locoregional - hepatic metastasis - ablation - chemoembolization - radioembolizationPublikationsverlauf
Artikel online veröffentlicht:
11. Dezember 2020
© 2020. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Ferlay J, Soerjomataram I, Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (05) E359-E386
- 2 Hagemeister Jr FB, Buzdar AU, Luna MA, Blumenschein GR. Causes of death in breast cancer: a clinicopathologic study. Cancer 1980; 46 (01) 162-167
- 3 Kenny LM, Orsi F, Adam A. Interventional radiology in breast cancer. Breast 2017; 35: 98-103
- 4 Adam R, Aloia T, Krissat J. et al. Is liver resection justified for patients with hepatic metastases from breast cancer?. Ann Surg 2006; 244 (06) 897-907 , discussion 907–908
- 5 Modi S, Saura C, Yamashita T. et al; DESTINY-Breast01 Investigators. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 2020; 382 (07) 610-621
- 6 Waks AG, Winer EP. Breast cancer treatment: a review. JAMA 2019; 321 (03) 288-300
- 7 Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016; 13 (11) 674-690
- 8 Atalay G, Biganzoli L, Renard F. et al; EORTC Breast Cancer and Early Clinical Studies Groups. Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 2003; 39 (17) 2439-2449
- 9 Cardoso F, Costa A, Senkus E. et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 2017; 28 (12) 3111-3111
- 10 Kobayashi T, Ichiba T, Sakuyama T. et al. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer 2012; 19 (03) 218-237
- 11 Seidensticker M, Garlipp B, Scholz S. et al. Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study). BMC Cancer 2015; 15: 517
- 12 Ruiz A, Sebagh M, Wicherts DA. et al. Long-term survival and cure model following liver resection for breast cancer metastases. Breast Cancer Res Treat 2018; 170 (01) 89-100
- 13 Caralt M, Bilbao I, Cortés J. et al. Hepatic resection for liver metastases as part of the “oncosurgical” treatment of metastatic breast cancer. Ann Surg Oncol 2008; 15 (10) 2804-2810
- 14 Kim JY, Park JS, Lee SA. et al. Does liver resection provide long-term survival benefits for breast cancer patients with liver metastasis? A single hospital experience. Yonsei Med J 2014; 55 (03) 558-562
- 15 Polistina F, Costantin G, Febbraro A, Robusto E, Ambrosino G. Aggressive treatment for hepatic metastases from breast cancer: results from a single center. World J Surg 2013; 37 (06) 1322-1332
- 16 Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 2012; 83 (03) 878-886
- 17 Palma DA, Olson RA, Harrow S. et al. Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial. Int J Radiat Oncol Biol Phys 2018; 102 (03) S3-S4
- 18 Chmura SJ, Winter K, Salama JK. et al. Phase I trial of stereotactic body radiation therapy (SBRT) to multiple metastatic sites: a NRG oncology study. Int J Radiat Oncol 2018; 102 (03) S68-S69
- 19 Palma DA, Olson R, Harrow S. et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019; 393 (10185): 2051-2058
- 20 Kucharczyk MJ, Parpia S, Walker-Dilks C, Banfield L, Swaminath A. Ablative therapies in metastatic breast cancer: a systematic review. Breast Cancer Res Treat 2017; 164 (01) 13-25
- 21 Sofocleous CT, Nascimento RG, Gonen M. et al. Radiofrequency ablation in the management of liver metastases from breast cancer. AJR Am J Roentgenol 2007; 189 (04) 883-889
- 22 Jakobs TF, Hoffmann R-T, Schrader A. et al. CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. Cardiovasc Intervent Radiol 2009; 32 (01) 38-46
- 23 Meloni MF, Andreano A, Laeseke PF, Livraghi T, Sironi S, Lee Jr FT. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation--intermediate and long-term survival rates. Radiology 2009; 253 (03) 861-869
- 24 Ridouani F, Solomon SB, Bryce Y, Bromberg JF, Sofocleous CT, Deipolyi AR. Predictors of progression-free survival and local tumor control after percutaneous thermal ablation of oligometastatic breast cancer: retrospective study. J Vasc Interv Radiol 2020; 31 (08) 1201-1209
- 25 Sadot E, Lee SY, Sofocleous CT. et al. Hepatic resection or ablation for isolated breast cancer liver metastasis: a case-control study with comparison to medically treated patients. Ann Surg 2016; 264 (01) 147-154
- 26 Niikura N, Costelloe CM, Madewell JE. et al. FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist 2011; 16 (08) 1111-1119
- 27 Ryan ER, Sofocleous CT, Schöder H. et al. Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. Radiology 2013; 268 (01) 288-295
- 28 Barral M, Auperin A, Hakime A. et al. Percutaneous thermal ablation of breast cancer metastases in oligometastatic patients. Cardiovasc Intervent Radiol 2016; 39 (06) 885-893
- 29 Bale R, Putzer D, Schullian P. Local treatment of breast cancer liver metastasis. Cancers (Basel) 2019; 11 (09) 1341
- 30 Pekar G, Hofmeyer S, Tabár L. et al. Multifocal breast cancer documented in large-format histology sections: long-term follow-up results by molecular phenotypes. Cancer 2013; 119 (06) 1132-1139
- 31 Salem R, Gilbertsen M, Butt Z. et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013; 11 (10) 1358-1365.e1
- 32 Saxena A, Kapoor J, Meteling B, Morris DL, Bester L. Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients. Ann Surg Oncol 2014; 21 (04) 1296-1303
- 33 Jakobs TF, Hoffmann R-T, Fischer T. et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 2008; 19 (05) 683-690
- 34 Fendler WP, Lechner H, Todica A. et al. Safety, efficacy, and prognostic factors after radioembolization of hepatic metastases from breast cancer: a large single-center experience in 81 patients. J Nucl Med 2016; 57 (04) 517-523
- 35 Cianni R, Pelle G, Notarianni E. et al. Radioembolisation with (90)Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. Eur Radiol 2013; 23 (01) 182-189
- 36 Pieper CC, Meyer C, Wilhelm KE. et al. Yttrium-90 radioembolization of advanced, unresectable breast cancer liver metastases - a single-center experience. J Vasc Interv Radiol 2016; 27 (09) 1305-1315
- 37 Bilbao JL, Iezzi R, Goldberg SN. et al. The ten commandments of hepatic radioembolization: expert discussion and report from Mediterranean Interventional Oncology (MIOLive) congress 2017. Eur Rev Med Pharmacol Sci 2017; 21 (18) 4014-4021
- 38 Deipolyi AR, Riedl CC, Bromberg J. et al. Association of PI3K pathway mutations with early positron-emission tomography/CT imaging response after radioembolization for breast cancer liver metastases: results of a single-center retrospective pilot study. J Vasc Interv Radiol 2018; 29 (09) 1226-1235
- 39 Haug AR, Tiega Donfack BP, Trumm C. et al. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med 2012; 53 (03) 371-377
- 40 Chalabi M, Fanchi LF, Dijkstra KK. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020; 26 (04) 566-576
- 41 Deipolyi AR, England RW, Ridouani F. et al. PET/CT imaging characteristics after radioembolization of hepatic metastasis from breast cancer. Cardiovasc Intervent Radiol 2020; 43 (03) 488-494
- 42 Martin RC, Robbins K, Fagés JF. et al. Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin. Breast Cancer Res Treat 2012; 132 (02) 753-763
- 43 Vogl TJ, Naguib NN, Nour-Eldin N-E, Eichler K, Zangos S, Gruber-Rouh T. Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. Eur Radiol 2010; 20 (01) 173-180
- 44 Chang J, Charalel R, Noda C. et al. Liver-dominant breast cancer metastasis: a comparative outcomes study of chemoembolization versus radioembolization. Anticancer Res 2018; 38 (05) 3063-3068
- 45 Li XP, Meng Z-Q, Guo W-J, Li J. Treatment for liver metastases from breast cancer: results and prognostic factors. World J Gastroenterol 2005; 11 (24) 3782-3787
- 46 Mouli SK, Gupta R, Sheth N, Gordon AC, Lewandowski RJ. Locoregional therapies for the treatment of hepatic metastases from breast and gynecologic cancers. Semin Intervent Radiol 2018; 35 (01) 29-34
- 47 Vlastos G, Smith DL, Singletary SE. et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol 2004; 11 (09) 869-874
- 48 van Walsum GAM, de Ridder JAM, Verhoef C. et al; Dutch Liver Surgeons Group. Resection of liver metastases in patients with breast cancer: survival and prognostic factors. Eur J Surg Oncol 2012; 38 (10) 910-917
- 49 Abbott DE, Brouquet A, Mittendorf EA. et al. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery 2012; 151 (05) 710-716
- 50 Mariani P, Servois V, De Rycke Y. et al. Liver metastases from breast cancer: Surgical resection or not? A case-matched control study in highly selected patients. Eur J Surg Oncol 2013; 39 (12) 1377-1383
- 51 Margonis GA, Buettner S, Sasaki K. et al. The role of liver-directed surgery in patients with hepatic metastasis from primary breast cancer: a multi-institutional analysis. HPB (Oxford) 2016; 18 (08) 700-705
- 52 Ruiz A, van Hillegersberg R, Siesling S. et al. Surgical resection versus systemic therapy for breast cancer liver metastases: Results of a European case matched comparison. Eur J Cancer 2018; 95: 1-10
- 53 Wieners G, Mohnike K, Peters N. et al. Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy - a phase II-study. Radiother Oncol 2011; 100 (02) 314-319
- 54 Mahadevan A, Blanck O, Lanciano R. et al. Stereotactic body radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry. Radiat Oncol 2018; 13 (01) 26
- 55 Onal C, Guler OC, Yildirim BA. Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy. Breast 2018; 42: 150-156
- 56 Veltri A, Gazzera C, Barrera M. et al. Radiofrequency thermal ablation (RFA) of hepatic metastases (METS) from breast cancer (BC): an adjunctive tool in the multimodal treatment of advanced disease. Radiol Med (Torino) 2014; 119 (05) 327-333
- 57 Kümler I, Parner VK, Tuxen MK. et al. Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer. Radiol Med (Torino) 2015; 120 (06) 536-541
- 58 Bai X-M, Yang W, Zhang Z-Y. et al. Long-term outcomes and prognostic analysis of percutaneous radiofrequency ablation in liver metastasis from breast cancer. Int J Hyperthermia 2019; 35 (01) 183-193
- 59 Maes T, Wildiers H, Heye S. et al. Intra-hepatic mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer. Breast Cancer Res Treat 2008; 110 (01) 135-142
- 60 Cho SW, Kitisin K, Buck D. et al. Transcatheter arterial chemoembolization is a feasible palliative locoregional therapy for breast cancer liver metastases. Int J Surg Oncol 2010; 2010: 251621
- 61 Duan XF, Dong NN, Zhang T, Li Q. Treatment outcome of patients with liver-only metastases from breast cancer after mastectomy: a retrospective analysis. J Cancer Res Clin Oncol 2011; 137 (09) 1363-1370
- 62 Nielsen DL, Nørgaard H, Vestermark LW. et al. Intrahepatic and systemic therapy with oxaliplatin combined with capecitabine in patients with hepatic metastases from breast cancer. Breast 2012; 21 (04) 556-561
- 63 Eichler K, Jakobi S, Gruber-Rouh T, Hammerstingl R, Vogl TJ, Zangos S. Transarterial chemoembolisation (TACE) with gemcitabine: phase II study in patients with liver metastases of breast cancer. Eur J Radiol 2013; 82 (12) e816-e822
- 64 Damian S, Tessari A, Capri G. et al. Fondazione IRCCS Istituto Nazionale dei Tumori M, Fondazione IRCCS Istituto Nazionale dei Tumori M. Hepatic trans-arterial chemoembolization (TACE) in metastatic breast cancer. Accessed July 29, 2020 at: https://meetinglibrary.asco.org/record/86304/abstract
- 65 Lin Y-T, Médioni J, Amouyal G, Déan C, Sapoval M, Pellerin O. Doxorubicin-loaded 70-150 μm microspheres for liver-dominant metastatic breast cancer: results and outcomes of a pilot study. Cardiovasc Intervent Radiol 2017; 40 (01) 81-89
- 66 Gordon AC, Gradishar WJ, Kaklamani VG. et al. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. J Vasc Interv Radiol 2014; 25 (10) 1523-1532 , 1532.e1–1532.e2
- 67 Bangash AK, Atassi B, Kaklamani V. et al. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol 2007; 18 (05) 621-628